ALEXANDER M. M. SHEPHERD, M.D., Ph.D.; MIN-SHUNG LIN, M.D.; T. KENT KEETON, Ph.D.
Metoprolol is the only cardioselective (β1) beta-adrenergic antagonist approved for use in the United States. This agent may be preferable to nonselective β-adrenergic blocking agents in stressful situations in which nonselective β1 and β2 blockade would permit unopposed epinephrine induced α-adrenergic vasoconstriction and hypertension (1, 2). Because insulin-induced hypoglycemia may result in elevated levels of epinephrine, metoprolol has been recommended for use in diabetic hypertensive patients in preference to propranolol (3, 4). We report a case of severe hypertension induced by hypoglycemia in a diabetic hypertensive patient receiving metoprolol.
A 60-year-old man was admitted to hospital with a 20-year history
SHEPHERD AMM, LIN M, KEETON TK. Hypoglycemia-Induced Hypertension in a Diabetic Patient on Metoprolol. Ann Intern Med. ;94:357–358. doi: 10.7326/0003-4819-94-3-357
Download citation file:
Published: Ann Intern Med. 1981;94(3):357-358.
Cardiology, Coronary Risk Factors, HIV, Hypertension, Infectious Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use